Commentary: “Bridging innovation and equity: the evolving landscape of CAR T-cell therapy access in Brazil” The Uruguayan pediatric experience

Bridging innovation and equity: the evolving landscape of CAR T-cell therapy access in Brazil

10.3389/frhem.2026.1813861 · 2026

Latin America and evolving oncotherapeutics using CAR T cells, conjugated antibodies, and bispecific antibodies

10.1016/j.bglo.2025.100007 · 2025

Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future

10.1097/hs9.0000000000000524 · 2021

Cáncer infantil en Uruguay: una alianza público-privada que logra equidad, ciencia y resultados [Childhood cancer in Uruguay: A public-private partnership that delivers equity, science, and resultsCâncer infantil no Uruguai: uma parceria público-privada que promove a equidade, a ciência e os resultados]

10.26633/rpsp.2026.61 · 2026

Point-of-care CAR T-cell therapy: toward broader access

10.1182/bloodadvances.2025017298 · 2025

Improving chimeric antigen receptor T access in Latin America: promises, barriers, and a call to action

10.1200/go-25-00760 · 2026

Myeloablative conditioning regimen in haploidentical stem cell transplantation with posttransplant cyclophosphamide in children with high-risk hematologic Malignancies

10.1097/mph.0000000000002406 · 2022

Risk factors and outcome of chimeric antigen receptor T-cell patients admitted to pediatric intensive care unit: CART-PICU study